CMB International Maintains "Buy" on Sino Biopharm, Adjusts Target Price to HK$8.7

Stock News03-31

CMB International has issued a research report reiterating a "Buy" rating for SINO BIOPHARM (01177). The financial institution revised its target price for the group down to HK$8.7 from HK$9.4, based on a discounted cash flow (DCF) valuation, reflecting a downward adjustment in expectations for non-BD revenue. SINO BIOPHARM reported its 2025 financial results, showing a 10.3% year-on-year increase in revenue to RMB 318.3 billion. Revenue from innovative products grew by 26.2% year-on-year to RMB 15.2 billion, accounting for 47.8% of total revenue. Adjusted net profit attributable to shareholders rose by 31.4% year-on-year to RMB 45.4 billion. Excluding dividends from Sinovac Life Sciences, the adjusted net profit still increased by 15% year-on-year. With generic drug revenue stabilizing and sales of innovative drugs continuing to gain momentum, the institution believes the company's performance will maintain steady growth this year. It forecasts that the company's revenue for 2026 to 2028 will grow year-on-year by 13.5%, 7.1%, and 9.2% respectively (non-BD revenue: 10.5%, 10%, 9.2%), while adjusted net profit attributable to shareholders is projected to increase by 5.4%, 8.3%, and 10.5% year-on-year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1189732629?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 13:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189732629","market":"fut","top_or_hot":-1,"title":"CMB International Maintains \"Buy\" on Sino Biopharm, Adjusts Target Price to HK$8.7","media":"Stock News","content":"<p>CMB International has issued a research report reiterating a \"Buy\" rating for SINO BIOPHARM (01177). The financial institution revised its target price for the group down to HK$8.7 from HK$9.4, based on a discounted cash flow (DCF) valuation, reflecting a downward adjustment in expectations for non-BD revenue. SINO BIOPHARM reported its 2025 financial results, showing a 10.3% year-on-year increase in revenue to RMB 318.3 billion. Revenue from innovative products grew by 26.2% year-on-year to RMB 15.2 billion, accounting for 47.8% of total revenue. Adjusted net profit attributable to shareholders rose by 31.4% year-on-year to RMB 45.4 billion. Excluding dividends from Sinovac Life Sciences, the adjusted net profit still increased by 15% year-on-year. With generic drug revenue stabilizing and sales of innovative drugs continuing to gain momentum, the institution believes the company's performance will maintain steady growth this year. It forecasts that the company's revenue for 2026 to 2028 will grow year-on-year by 13.5%, 7.1%, and 9.2% respectively (non-BD revenue: 10.5%, 10%, 9.2%), while adjusted net profit attributable to shareholders is projected to increase by 5.4%, 8.3%, and 10.5% year-on-year.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CMB International Maintains \"Buy\" on Sino Biopharm, Adjusts Target Price to HK$8.7</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCMB International Maintains \"Buy\" on Sino Biopharm, Adjusts Target Price to HK$8.7\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-31 13:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CMB International has issued a research report reiterating a \"Buy\" rating for SINO BIOPHARM (01177). The financial institution revised its target price for the group down to HK$8.7 from HK$9.4, based on a discounted cash flow (DCF) valuation, reflecting a downward adjustment in expectations for non-BD revenue. SINO BIOPHARM reported its 2025 financial results, showing a 10.3% year-on-year increase in revenue to RMB 318.3 billion. Revenue from innovative products grew by 26.2% year-on-year to RMB 15.2 billion, accounting for 47.8% of total revenue. Adjusted net profit attributable to shareholders rose by 31.4% year-on-year to RMB 45.4 billion. Excluding dividends from Sinovac Life Sciences, the adjusted net profit still increased by 15% year-on-year. With generic drug revenue stabilizing and sales of innovative drugs continuing to gain momentum, the institution believes the company's performance will maintain steady growth this year. It forecasts that the company's revenue for 2026 to 2028 will grow year-on-year by 13.5%, 7.1%, and 9.2% respectively (non-BD revenue: 10.5%, 10%, 9.2%), while adjusted net profit attributable to shareholders is projected to increase by 5.4%, 8.3%, and 10.5% year-on-year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BZ08YS42.EUR","symbol_name":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","start_time":0,"source_url":"","article_id":"1189732629","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189732629","pubTimestamp":1774936246,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CMB International has issued a research report reiterating a \"Buy\" rating for SINO BIOPHARM (01177). The financial institution revised its target price for the group down to HK$8.7 from HK$9.4, based...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","01177":"中国生物制药","BK1589":"北水核心资产","BK1515":"抗疫概念","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","01477":"欧康维视生物-B","BK1191":"制药","BK1521":"挪威政府全球养老基金持仓","EWH":"香港ETF-iShares MSCI","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","BK1574":"生物医药B类股","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC"},"translate_title":"招银国际维持中国生物“买入”目标价调整至8.7港元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01477":1,"EWH":1,"01177":1},"content_text":"CMB International has issued a research report reiterating a \"Buy\" rating for SINO BIOPHARM (01177). The financial institution revised its target price for the group down to HK$8.7 from HK$9.4, based on a discounted cash flow (DCF) valuation, reflecting a downward adjustment in expectations for non-BD revenue. SINO BIOPHARM reported its 2025 financial results, showing a 10.3% year-on-year increase in revenue to RMB 318.3 billion. Revenue from innovative products grew by 26.2% year-on-year to RMB 15.2 billion, accounting for 47.8% of total revenue. Adjusted net profit attributable to shareholders rose by 31.4% year-on-year to RMB 45.4 billion. Excluding dividends from Sinovac Life Sciences, the adjusted net profit still increased by 15% year-on-year. With generic drug revenue stabilizing and sales of innovative drugs continuing to gain momentum, the institution believes the company's performance will maintain steady growth this year. It forecasts that the company's revenue for 2026 to 2028 will grow year-on-year by 13.5%, 7.1%, and 9.2% respectively (non-BD revenue: 10.5%, 10%, 9.2%), while adjusted net profit attributable to shareholders is projected to increase by 5.4%, 8.3%, and 10.5% year-on-year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1189732629","isCrawlerRequest":true}